Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORVASC vs ALPHAGAN P
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions across myocardial and vascular smooth muscle cell membranes, causing vasodilation and reduction in peripheral vascular resistance and blood pressure.
Alpha-2 adrenergic agonist; decreases intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.
Hypertension,Coronary artery disease (chronic stable angina, vasospastic angina, angiographically documented coronary artery disease in patients without heart failure or ejection fraction <40%)
Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
5–10 mg orally once daily; initial dose 5 mg, titrate based on response; maximum 10 mg/day.
One drop of 0.1% or 0.15% ophthalmic solution in the affected eye(s) three times daily, approximately 8 hours apart.
30-50 hours (terminal); allows once-daily dosing; steady-state achieved after 7-8 days.
Terminal elimination half-life: approximately 2 hours (range 1.5-3 hours) in aqueous humor after topical administration; systemic half-life: ~3 hours.
Extensively metabolized in the liver via CYP3A4 isoenzyme; metabolites are inactive.
Minimal systemic metabolism; undergoes extensive ocular metabolism. Systemic metabolism primarily hepatic via aldehyde oxidase and cytochrome P450 enzymes.
Renal: 60% as metabolites; Fecal: 20-25% as parent drug and metabolites; Biliary: ~10%.
Renal: approximately 70% unchanged; fecal: <10% as metabolites.
~93% bound to plasma proteins (primarily albumin).
Approximately 30% bound to plasma proteins (mainly albumin).
21 L/kg (high, indicating extensive tissue binding).
Vd: ~0.8 L/kg, indicating moderate tissue distribution; the drug distributes into aqueous humor and ocular tissues.
64-90% (oral); mean ~80%.
Topical ophthalmic: systemic bioavailability is approximately 80% due to absorption through nasal mucosa and gastrointestinal tract after drainage; oral bioavailability is high but not clinically used.
No dose adjustment required for any degree of renal impairment.
No specific dose adjustment recommended; use with caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential systemic accumulation.
For Child-Pugh Class A or B: start at 2.5 mg once daily, titrate cautiously; Child-Pugh Class C: no data, consider 2.5 mg once daily.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), consider using the lowest concentration (0.1%) and monitor for adverse effects.
For hypertension: 2.5–5 mg orally once daily for children 6–17 years; for children <6 years: 0.05–0.2 mg/kg once daily, not to exceed 5 mg/day.
Not recommended for use in children under 2 years of age. For children ≥2 years, same as adult dosing (one drop of 0.1% solution three times daily).
Start at 2.5 mg orally once daily due to increased systemic exposure and reduced clearance; titrate slowly based on tolerance and response.
No specific dose adjustment required, but monitor for systemic effects (e.g., hypotension, bradycardia) due to potential age-related reduced clearance.
None
None
Risk of hypotension especially in patients with severe aortic stenosis,Worsening angina and myocardial infarction upon abrupt withdrawal or dose increase,Increased frequency, duration, or severity of angina on initiation or dose increase,Peripheral edema,Use in heart failure patients with reduced ejection fraction may increase risk of pulmonary edema and worsening heart failure,Hepatic impairment may require dose adjustment
May cause fatigue/drowsiness and dizziness, impairing ability to drive or operate machinery,Use with caution in patients with severe cardiovascular disease or depression,May cause allergic reactions, including ocular pruritus and hyperemia,May reduce heart rate and blood pressure,Caution in patients with renal impairment
Hypersensitivity to amlodipine or any component of the formulation
Hypersensitivity to brimonidine or any component,Neonates and infants (especially those less than 2 years of age),Concomitant use with MAO inhibitors
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 metabolism, increasing amlodipine levels and risk of adverse effects. No other significant food interactions.
No specific food interactions. Avoid alcohol as it may exacerbate drowsiness or dizziness.
No teratogenic effects in animal studies. FDA Pregnancy Category C. First trimester: insufficient human data; risk cannot be excluded. Second and third trimesters: may cause fetal hypoxia due to maternal hypotension; avoid use in preeclampsia.
Brimonidine (ALPHAGAN P) is category B. Animal studies show no fetal harm at doses up to 2.5 mg/kg/day. No adequate human studies in first trimester. Potential for reduced placental perfusion due to alpha-2 agonism; avoid in late pregnancy (risk of uterine contractions).
Amlodipine is excreted in human milk. M/P ratio not determined. Limited data suggest low transfer. Consider risk of hypotension in infant.
Brimonidine is excreted in breast milk; M/P ratio unknown. Caution due to risk of infant hypotension, bradycardia, and CNS depression. Consider alternative if breastfeeding.
No specific dose adjustment recommended. Use lowest effective dose due to increased plasma volume and renal clearance; pharmacodynamic changes may require titration.
No dose adjustment required for ophthalmic use; systemic absorption is minimal. However, consider lower concentration or alternative if multiple daily dosing used.
Norvasc (amlodipine) is a dihydropyridine calcium channel blocker with a long half-life (~30-50 hours), allowing once-daily dosing. Onset of action is gradual, reducing reflex tachycardia. It is effective for hypertension and chronic stable angina, but not for acute angina. Common side effects include peripheral edema, dizziness, and flushing. Avoid abrupt discontinuation to prevent rebound hypertension. Caution in patients with severe aortic stenosis or heart failure with reduced ejection fraction (NYHA III/IV).
Alphagan P (brimonidine tartrate) is a selective alpha-2 adrenergic agonist used to lower intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension. It reduces aqueous humor production and increases uveoscleral outflow. Onset of action is within 1-2 hours. It is available as 0.1% and 0.15% solutions, with 0.1% having fewer side effects. Avoid use with MAOIs and in patients with severe hepatic impairment. Monitor for systemic hypotension and bradycardia, especially in elderly. Rebound ocular hypertension may occur upon discontinuation.
Take Norvasc exactly as prescribed, usually once daily with or without food.,Do not stop taking this medication without consulting your doctor, as abrupt discontinuation can worsen blood pressure or chest pain.,Swallow the tablet whole; do not crush or chew.,Manage edema by elevating legs and avoiding prolonged standing; report severe swelling to your doctor.,Avoid grapefruit and grapefruit juice as they can increase blood levels of amlodipine and risk of side effects.,Limit alcohol intake, as it can lower blood pressure further.,Monitor blood pressure regularly and keep a log to share with your healthcare provider.
Instill one drop in the affected eye(s) three times daily, about 8 hours apart.,Wash hands before and after use. Avoid touching the dropper tip to any surface.,If using more than one ophthalmic drug, wait at least 5 minutes between applications.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Do not drive or operate machinery until you know how this medication affects you, as it may cause drowsiness or blurred vision.,Report persistent eye pain, redness, or vision changes to your healthcare provider.,Store at room temperature, away from heat and light. Do not freeze.,Dispose of any unused solution 28 days after first opening.
No interactions on record
No interactions on record
Common clinical questions about NORVASC vs ALPHAGAN P, answered by our medical review team.
NORVASC is a Calcium Channel Blocker (Antihypertensive) that works by Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions across myocardial and vascular smooth muscle cell membranes, causing vasodilation and reduction in peripheral vascular resistance and blood pressure.. ALPHAGAN P is a Alpha-2 Adrenergic Agonist (Ophthalmic) that works by Alpha-2 adrenergic agonist; decreases intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORVASC and ALPHAGAN P depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORVASC is: 5–10 mg orally once daily; initial dose 5 mg, titrate based on response; maximum 10 mg/day.. The standard adult dose of ALPHAGAN P is: One drop of 0.1% or 0.15% ophthalmic solution in the affected eye(s) three times daily, approximately 8 hours apart.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORVASC and ALPHAGAN P in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORVASC is classified as Category C. No teratogenic effects in animal studies. FDA Pregnancy Category C. First trimester: insufficient human data; risk cannot be excluded. Second and third trimesters: may cause fetal . ALPHAGAN P is classified as Category C. Brimonidine (ALPHAGAN P) is category B. Animal studies show no fetal harm at doses up to 2.5 mg/kg/day. No adequate human studies in first trimester. Potential for reduced placenta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.